OQS
KDNY

Occudo Quantitative Strategies’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Occudo Quantitative Strategies’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-23,783
Closed -$468K – 1489
2022
Q3 		$468K Buy
23,783
+5,616
+31% +$113K 0.04% 688
2022
Q2 		$318K Buy
+18,167
New +$285K 0.03% 773

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Occudo Quantitative Strategies's KDNY Position: Q4 2022 in Review

Occudo Quantitative Strategies sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2022, closing a stake of 23,783 shares — an estimated $468K sold.

Occudo Quantitative Strategies first reported a position in KDNY in Q2 2022 and held it in 2 quarters. The position peaked at $468K in Q3 2022. 155 funds tracked by Wall St. Rank hold KDNY as of Q4 2022.

  • Occudo Quantitative Strategies reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 23,783 Chinook Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $468K.
  • Occudo Quantitative Strategies first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Occudo Quantitative Strategies's Chinook Therapeutics, Inc. Common Stock position peaked at $468K in Q3 2022.
  • 155 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Occudo Quantitative Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.